Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Industry: Healthcare

OFF LIST - 2389 consecutive market days: OFF LIST as of 12/07/2006 Through 11/14/2016

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. The company has a development agreement with Enable Injections, Inc. to develop wearable devices for subcutaneous delivery of high-volume therapeutics. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.

Current Quote*
Last: $13.875
Change: -0.475
Book: $3.972
Volume: 113,071

As Of: 02/15 13:37 ET
*Quotes delayed by 20min.

Graphs for APLS

3 Month Graph

6 Month Graph

1 Year Graph